Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “TPX-100 (200 mg per dose) will be administered once-weekly (Week 1, 2, 3 \& 4) to a single target knee of the subject for 4 injections. TPX-100 can be administered by conventional methods such as subcutaneous or intra-articular injection.”In the company’s words, NCT06865079 on ClinicalTrials.gov
- Tested for
- Osteoarthritis (OA) of the Knee
- Main trialPhase 2
- “53-Week Study Evaluating the Safety and Efficacy of Intra-articular (IA) Injections of TPX-100 vs Placebo in Subjects with Mild to Severe Tibio-Femoral Osteoarthritis of the Knee”In the company’s words, NCT06865079 on ClinicalTrials.gov
Other drugs for Osteoarthritis (OA) of the Knee
- JOINTSTEMR-Bio · Phase 3
- DiacereinTRB Chemedica · Phase 3
- Mesenchymal Stem CellsWuxi Cellular Biopharmaceutical Group Ltd. · Phase 3
- PTP-01Doron Therapeutics Inc. · Phase 3
- Sodium hyaluronateIBSA Institut Biochimique SA · Phase 3
- Pentosan Polysulfate SodiumParadigm Biopharmaceuticals Ltd. · Phase 3
Coming up1
- 25 Mar 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 25 Mar 2027 | 53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026